Compare PKE & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PKE | LXRX |
|---|---|---|
| Founded | 1954 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 389.4M | 425.2M |
| IPO Year | N/A | 2000 |
| Metric | PKE | LXRX |
|---|---|---|
| Price | $21.28 | $1.22 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $3.23 |
| AVG Volume (30 Days) | 107.3K | ★ 1.6M |
| Earning Date | 01-13-2026 | 11-06-2025 |
| Dividend Yield | ★ 2.33% | N/A |
| EPS Growth | ★ 5.81 | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | $63,128,000.00 | ★ $70,864,000.00 |
| Revenue This Year | N/A | $56.61 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $59.59 | ★ N/A |
| Revenue Growth | 7.63 | ★ 1255.21 |
| 52 Week Low | $11.97 | $0.28 |
| 52 Week High | $22.55 | $1.66 |
| Indicator | PKE | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 61.09 | 43.16 |
| Support Level | $19.84 | $1.12 |
| Resistance Level | $22.55 | $1.32 |
| Average True Range (ATR) | 0.77 | 0.09 |
| MACD | 0.15 | -0.01 |
| Stochastic Oscillator | 60.38 | 31.54 |
Park Aerospace Corp designs is an aerospace company which develops and manufactures solution and hot-melt composite materials used to produce composite structures for the aerospace markets. Its composite materials include film adhesives and lightning strike protection materials. Its composite materials are used to produce primary and secondary structures for jet engines, large and regional transport aircraft, military aircraft, Unmanned Aerial Vehicles (UAVs commonly referred to as drones), business jets, general aviation aircraft and rotary wing aircraft. The Company's products are sold to customers in North America, Asia and Europe.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.